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(PAF) is believed to amplify the activity of
key mediators of the systemic inflamma-
tory response syndrome (SIRS) in acute
pancreatitis, resulting in multiorgan dys-
function syndrome. We tested the hypoth-
esis that a potent PAF antagonist,
lexipafant, could dampen SIRS and re-
duce organ failure in severe acute pan-
creatitis.
Methods—We conducted a randomised,
double blind, placebo controlled, multi-
centre trial of lexipafant (100 mg/24 hours
intravenously for seven days commenced
within 72 hours of the onset of symptoms)
involving 290 patients with an APACHE II
score >6. Power calculations assumed that
complications would be reduced from 40%
to 24%. Secondary end points studied
included severity of organ failure, mark-
ers of the inflammatory response, and
mortality rate.
Findings—Overall, 80/138 (58%) patients
in the placebo group and 85/148 (57%) in
the lexipafant group developed one or
more organ failures. The primary hypoth-
esis was invalidated by the unexpected
finding that 44% of patients had organ
failure on entry into the study; only 39
(14%) developed new organ failure. Organ
failure scores were reduced in the lexipa-
fant group only on day 3: median change
−1 (range −4 to +8) versus 0 (−4 to +10) in
the placebo group (p=0.04). Systemic sep-
sis aVected fewer patients in the lexipafant
group (13/138 v 4/148; p=0.023). Local
complications occurred in 41/138 (30%)
patients in the placebo group and in 30/148
(20%) in the lexipafant group (20%;
p=0.065); pseudocysts developed in 19
(14%) and eight (5%) patients, respec-
tively (p=0.025). Deaths attributable to
acute pancreatitis were not significantly
diVerent. Interleukin 8, a marker of
neutrophil activation, and E-selectin, a
marker of endothelial damage, decreased
more rapidly in the lexipafant group (both
p<0.05); however, absolute values were not
diVerent between the two groups.
Interpretation—The high incidence of
organ failure within 72 hours of the onset
of symptoms undermined the primary
hypothesis, and power calculations for
future studies in severe acute pancreatitis
will need to allow for this. Lexipafant had
no eVect on new organ failure during
treatment. This adequately powered study
has shown that antagonism of PAF activity
on its own is not suYcient to ameliorate
SIRS in severe acute pancreatitis
(Gut 2001;48:62–69)
Keywords: platelet activating factor; organ failure;
systemic inflammatory response syndrome; lexipafant;
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Severe acute pancreatitis is characterised by
systemic organ failure as well as local pancre-
atic complications1 and is still associated with a
mortality rate of 15–30%, despite continuing
improvements in critical care.2 Although the
use of endoscopic sphincterotomy in patients
with gall stones,3–5 selective gut decontamina-
tion,6 and prophylactic antibiotics6 7 may be of
benefit, specific medical therapy has not been
successful.8 9
A change in the understanding of the patho-
physiology of acute pancreatitis occurred with
the suggestion that the initial phase of severe
acute pancreatitis depends on neutrophil acti-
vation,10 accompanied by the systemic inflam-
matory response syndrome (SIRS).11 Organ
failure is more important than pancreatic
necrosis in the prediction of death in acute
pancreatitis.12 Proinflammatory cytokines in-
cluding interleukin (IL)-1â, IL-6., IL-8,
tumour necrosis factor á, and platelet activat-
ing factor (PAF), and the anti-inflammatory
cytokines IL-2 and IL-10, are implicated in the
pathogenesis of SIRS in acute pancreatitis.13
This understanding has led to the development
of an alternative treatment strategy aimed at
interrupting the inflammatory response in an
attempt to reduce the degree of SIRS and mul-
tiple organ dysfunction syndrome
(MODS).2 14–18 PAF may be induced from key
cellular systems involved in SIRS, including
endothelial cells, monocytes, neutrophils, and
Abbreviations used in this paper: PAF, platelet
activating factor; SIRS, systemic inflammatory
response syndrome; IL, interleukin; MODS, multiple
organ dysfunction syndrome; CRP, C reactive protein;
PMN, polymorphonuclear; ERCP/ES, endoscopic
retrograde cholangiopancreatography/endoscopic
sphincterotomy; LREC, local research ethics
committee; CT, computerised tomography; OFS,
organ failure score; AUC, area under the curve.
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platelets, resulting in their activation with
release of other proinflammatory cytokines.19
Moreover, PAF increases vascular permeabil-
ity, induces leucocyte infiltration, oedema, and
tissue injury, and has a negative inotropic
eVect.20 PAF is a particularly relevant target for
therapy as its administration can induce
experimental acute pancreatitis17 and because
PAF antagonists ameliorate acute pancreatitis
in other experimental models.17 20–23
Lexipafant is one of the most powerful PAF
antagonists so far developed.24 Two phase II
randomised trials involving a total of 133
patients with acute pancreatitis showed signifi-
cant improvement in organ failure scores
(OFSs).14 25 This report describes the results of
a double blind, placebo controlled, randomised
trial of lexipafant in consecutively screened




This was a multicentre, double blind, placebo
controlled, randomised, parallel group, phase
III study designed and conducted in accord-
ance with the recommendations of the EEC
Committee for Proprietary Medicinal Prod-
ucts.26 The primary objective was to determine
if an infusion of lexipafant given within 72
hours of the onset of symptoms of predicted
severe acute pancreatitis could reduce the
frequency of systemic (organ failure) or local
complications.1 The dose selected had been
used in a phase II study25 (100 mg daily by
infusion for seven days). This dose produced
plasma concentrations of lexipafant of more
than 10 times those needed to abolish the
eVects of PAF in ex vivo experiments. Selection
of patients with an APACHE II score >6 was
expected to produce a frequency of severe (that
is, complicated) acute pancreatitis of 40%. To
show a 40% reduction in the frequency of
complications (from 40% to 24%) given
á=0.05 with a power of 80%, each group
required 150 patients. No interim analysis was
carried out. Secondary objectives were assess-
ment of the influence of lexipafant on measures
of disease severity, as shown by OFS, incidence
of sepsis, and plasma markers of the inflamma-
tory response (IL-8, E-selectin, IL-6, C
reactive protein (CRP), and polymorphonu-
clear (PMN) elastase), duration of hospital and
intensive care unit (ICU) stay, and mortality
rate. Patients were assessed daily for nine days
and then weekly until discharge from hospital.
All complications, adverse events, and any
deaths, in hospital or after discharge, were
recorded. The clinical care of the patients
remained with the responsible clinician in each
hospital. All patients underwent ultrasonogra-
phy to detect gall stones. Computerised
tomography (CT) was undertaken on clinical
grounds at the request of the responsible clini-
cian. Similarly, the use of antibiotics and endo-
scopic retrograde cholangiopancreatography
and endoscopic sphincterotomy (ERCP/ES)
was not specified, although recorded. As the
study neared completion, a closure date was set
to allow projected inclusion of 300 patients.
Study location
Eighteen centres (see appendix 1) recruited
patients from 78 hospitals in the UK between
November 1994 and August 1996 (see appen-
dix 2). Study personnel from each centre
visited adjacent hospitals to recruit patients
and to administer trial medication.
Inclusion and exclusion criteria
All of the following were required for inclusion:
severe abdominal pain of <72 hours duration at
initiation of study treatment; serum amylase
level >3 times the upper limit of the normal
range in the 72 hours before study entry; a clini-
cal picture consistent with acute pancreatitis;
and an APACHE II score27 >6 in the 24 hours
before study entry. Patients were excluded for
any one of the following reasons: age <18 or >80
years; premenopausal women in whom preg-
nancy could not be excluded; pancreatitis
believed to be due to trauma, surgery, neoplasm,
or ERCP/ES; patients unsuitable for ventilation
because of pre-existing illness; patients who had
received other investigational agents in the
preceding three months; patients receiving oral
anticoagulant therapy; and patients who had
previously received lexipafant.
Assignment and drug administration
After enrolment, patients were randomly allo-
cated to receive an intravenous infusion contain-
ing lexipafant (British Biotech Pharmaceuticals
Ltd, Oxford, UK) or an identical placebo
infusion. Lexipafant was presented in ampoules
containing 5 mg/ml in aqueous solution buV-
ered to pH 3.9–4.4. Placebo ampoules con-
tained vehicle only. The medication was diluted
in 0.9% NaCl or 5% dextrose solution and
infused over 10 minutes to provide a 4 mg load-
ing dose, followed by 4 mg in 20 ml/h for 168
hours.
Ethical considerations
The study was conducted in accordance with
recommendations for good clinical practice.26
In each participating hospital the local research
ethics committee (LREC) gave approval for the
study before patient recruitment began and all
amendments were submitted to the LREC.
Informed consent was obtained from patients
or, if they were unable because of severity of
illness, from their next of kin.
ASSESSMENT OF OUTCOME
Organ failure
Organ failure was defined as follows: cardio-
vascular failure if systolic blood pressure was
<90 mm Hg despite fluid replacement; respira-
tory failure if the PaO2/FiO2 ratio was <300 mm
Hg; central nervous system failure if the Glasgow
coma score was <13; coagulopathy if platelet
count was <80×109/l; and renal failure if plasma
creatinine was >170 µmol/l.
Local complications
Pancreatic necrosis was diagnosed by CT show-
ing non-enhancing pancreatic parenchyma
(tissue density <50 Hounsfield units after
intravenous contrast) >3 cm in size, or >30%
of the area of the pancreas. Pancreatic abscess
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was defined as a circumscribed intra-
abdominal collection of pus in the proximity of
the pancreas containing little or no necrotic
material. Pseudocyst was defined as fluid collec-
tion rich in pancreatic enzymes, enclosed in a
non-epithelial wall and present at least four
weeks after the onset of acute pancreatitis.
Acute fluid collections, which occurred within the
first four weeks of acute pancreatitis located in
or near the pancreas and lacking a wall of
granulation and fibrous tissue, were not
included as a complication.
Organ failure score (OFS)
OFS was calculated as suggested by Bernard
and colleagues28 (table 1). Hepatic failure was
not included in the calculation of OFS, in
accordance with the Atlanta criteria, because in
acute pancreatitis elevated bilirubin more
commonly represents biliary obstruction than
hepatocellular damage.
Sepsis
Sepsis was defined as two or more signs indica-
tive of SIRS, with simultaneous evidence of
infection shown by positive bacterial or fungal
cultures.29
Blood assays
Blood samples were obtained before study
entry, at 12 and 24 hours after entry, and for up
to nine days after admission to the study for
estimation of IL-8, E-selectin, IL-6, CRP, and
PMN elastase. Serum was stored at −20°C and
the assays were performed at a central
laboratory (Ravenscourt Laboratories). IL-8,
E-selectin, and IL-6 were determined using
Quantikine kits (Research and Diagnostic Sys-
tems, Minneapolis, USA). Detection limits
were 18 pg/ml for IL-8, <0.1 ng/ml for
E-selectin, and 0.35 pg/ml for IL-6. PMN
elastase was assayed using either the IMAC
technique or ecoline PMN elastase kits (both
Merck Ltd, Lutterworth, Leics, UK); the lower
limits of sensitivity of the assays were 8 µg/l and
4 µg/l, respectively. CRP was measured using
TINA-QUANT kits (Boehringer-Mannheim,
Germany). Routine haematology, biochemis-
try, coagulation, and urine analysis were
performed at the participating hospitals.
Deaths
These were categorised as attributable to acute
pancreatitis or otherwise by the principal
investigators, before the randomisation code was
broken. The protocol contained provision for
subgroup analysis of deaths in patients treated
within 48 hours of the onset of symptoms.
Serious adverse events
The principal investigator in each centre was
asked to decide whether in their opinion any
adverse advent was drug related. Lexipafant
levels were determined in blood samples from
patients with any adverse events.
STATISTICAL ANALYSIS
Data on the clinical record forms were entered
into a Clintrial database on a VAX 4015A
computer. All data entry was verified by an
independent observer by means of blinded
duplicated data entry. Data records were
downloaded into ASCII files and converted
into SAS version 6.11 data sets (SAS Ist, Cary,
North Caroline, USA). Categorical data were
analysed using the ÷2 test and Fisher’s exact
probability test. Continuous variables were
compared using the Wilcoxon rank sum test.
The probability of death was modelled using a
logistic regression analysis with duration of
symptoms before treatment and baseline OFS
as covariates together with an interaction of
treatment by duration of symptoms. The
estimated log odds ratio for death related to
symptom duration was calculated by: log
(odds: lexipafant group)−log (odds: placebo
group).30 An algorithm was written to allow
interpolation of missing data for calculation of
OFSs (see appendix 3). Changes from baseline
values of inflammatory markers were calcu-
lated for each patient, median values were plot-
ted, and the area under the curve (AUC) was
used for comparison of treatment groups.
Results
A total of 2340 patients were screened of whom
379 (16.2%) were eligible for the study but 88
were not recruited because consent was
withheld (n=80), study personnel were not
available (n=4), or LREC approval had not
been completed (n=4). Of the 291 (76.8%)
patients randomised, one withdrew from the
study before receiving any trial medication and
was not considered in any subsequent analysis.
Thus 139 were randomised to the placebo
group and 151 to the lexipafant group.
Table 1 Organ failure scores. Each organ failure was scored 0–4 as defined by Bernard and colleagues.28 The score for
each patient was the sum of the scores for each organ/system
Clinically significant organ dysfunction
Score 0 Normal 1 Mild 2 Moderate 3 Severe 4 Extreme
Cardiovascular
SBP (mm Hg) >90 <90 fluid
responsive
<90 Not fluid responsive <90 pH<7.3 <90 pH<7.2
Pulmonary
PaO2/FiO2 (mm Hg) >400 400–301 300–201 acute lung injury 200–101 ARDS <100 severe ARDS
CNS
Glasgow coma score 15 14–13 12–10 9–6 >5
Coagulation
Platelets (×109/1) >120 120–81 80–51 50–21 >20
Renal
Creatinine (µmol/1) <133 >133 to <169 >169 to <310 >310 to <440 >440
SPB, systolic blood pressure; PaO2, arterial oxygen tension; FiO2, inspired oxygen concentration (fraction); ARDS, adult respiratory
distress syndrome; CNS, central nervous system.
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Antibiotics were given to 75 (54%) patients
in the placebo group on the first day versus 72
(49%) in the lexipafant group; in the first week
these values were 100 (72%) and 97 (66%),
respectively. Ten patients in the placebo group
underwent ERCP/ES within 48 hours com-
pared with 11 in the lexipafant group. Between
three and seven days, the respective values were
eight and six patients, and after this, nine and
17 patients, respectively.
There were 42 (14%) deaths, of which 35
were attributed to acute pancreatitis. In three
cases death was not due to acute pancreatitis
but to multiple thrombotic episodes (placebo),
myocardial infarction, (lexipafant), and pulmo-
nary emboli (lexipafant) (one patient each).
Three patients died after having been dis-
charged from hospital following complete
recovery from acute pancreatitis: one each
from myocardial infarction at 115 days (pla-
cebo), brain stem infarction at 168 days
(lexipafant), and pneumonia complicating a
second attack of acute pancreatitis at 63 days
(placebo). One further patient (lexipafant)
died from metastatic carcinoma and was not
actively treated (major protocol violation).
Analysis of deaths attributable to pancreatitis
therefore was based on 136 patients in the pla-
cebo group and 147 in the lexipafant group (fig
1). Other outcome variables were analysed
after excluding patients with an incorrect diag-
nosis or major protocol violation (138 in the
placebo group and 148 in the lexipafant
group). Patient characteristics (table 2) and
aetiology were similar in the two groups.
COMPLICATIONS
Incidence of organ failure
We found that 126 (44%) of the 286 patients
already had organ failure on the day of admis-
sion and new organ failure developed in only
39 (14%) patients (table 3). The diVerence in
total frequency of organ failure was 0.5% (95%
confidence intervals (CI) −11 to +12%). New
organ failure developed in 21 of 79 patients
without organ failure who received placebo,
and in 18 of 81 who received lexipafant, a dif-
ference of 4% (95% CI −9 to +17%). These
diVerences between groups were not signifi-
cant.
Incidence of local complications
CT was performed in 62 (45%) patients in the
placebo group and in 56 (38%) in the
lexipafant group. Significantly more patients
developed a pseudocyst in the placebo group
(p=0.025) but overall the number of patients
who developed local complications in the two
Figure 1 Summary of patients treated. A total of 2340 patients were screened; 379 were
eligible and 291 were randomised. One patient withdrew after randomisation. Treatment
allocations, exclusions, and non-attributable deaths showing the basis for analysis of


























Table 2 Charactistics of all patients in the two treatment





Age (y) (median (range)) 63 (31–79) 63 (18–79)
Sex (M/F) 83/56 83/68
APACHE II score
(median (range)) 11 (4–29) 10 (5–24)
Aetiology
Gall stones* 66 (47%) 73 (48%)
Alcohol* 18 (13%) 20 (13%)
Other 3 (2%) 4 (3%)
Unknown 54 (40%) 55 (37%)
No with organ failure 59 (43%) 67 (44%)
Respiratory 53 (38%) 58 (39%)
Cardiovascular 2 (1%) 0
Renal 11 (8%) 10 (7%)
CNS 2 (1%) 0
Coagulation 3 (2%) 5 (3%)
Inflammatory markers (median (IQR))
IL-8 (pg/ml) 31 (0–69) 37 (0–80)
E-selectin (ng/ml) 67 (51–100) 70 (52–100)
IL-6 (pg/ml) 195 (54–297) 124 (46–243)
CRP (mg/l) 83 (43–142) 80 (34–144)
PMN elastase 173 (105–295) 185 (103–295)
Symptom duration before first dose
<24 hours 35 (25%) 34 (23%)
24–48 hours 63 (45%) 73 (48%)
>48 hours 41 (30%) 44 (29%)
IQR, interquartile range.
*Two placebo and one lexipafant patient had both gall stones
and alcohol.
Table 3 Incidence of organ failure, local complications,
and deaths in the two groups
Complications Placebo group Lexipafant group
Organ failure
On admission 59 (43%) 67 (45%)
Day 3 46 (33%) 40 (27%)
Day 7 36 (26%) 29 (20%)
Overall 80/138 (58%) 85/148 (57%)
Local complications
Pseudocyst 19 (14%) 8 (5%)a
Necrosis 29 (21%) 23 (16%)
Abscess 6 (4%) 5 (3%)
Overall 41/138 (30%) 30/148 (20%)b
Systemic sepsis 13/138 (9%) 4/148 (3%)c
Deaths
All attributable deaths 21/136 (15%) 14/147 (10%)
Attributable deaths in
patients treated <48 h 17/95 (18%) 8/104 (8%)d
aFisher’s exact test, p=0.025.
b÷2I=3.41, p=0.065.
cFisher’s exact test, p=0.023.
dFisher’s exact test, p=0.034.
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groups was not significantly diVerent (table 3).
Fifty nine (85%) of 71 patients with local com-
plications also had early organ failure; of the
165 patients with organ failure, 36% developed
local complications. Thirty six (45%) of 80
patients in the placebo group who had organ
failure developed local complications com-
pared with 23 (27%) of 85 patients in the lexi-
pafant group (÷2=5.78, p=0.016).
CHANGES IN OFS
Mean OFS decreased consistently from the
baseline score in the lexipafant group whereas
in the placebo group there was an initial
increase over days 1 and 2 (fig 2). The median
change at day 3 was zero (range −4 to +10) in
the placebo group and −1 (−4 to +8) in the
lexipafant group (p=0.04). There was no
significant diVerence in the change in OFS at
day 7 between the two groups (−1 (−5 to + 15)
and −1 (−6 to +9), respectively).
SYSTEMIC SEPSIS
Thirteen (9%) patients in the placebo group
developed sepsis compared with four (3%) in
the lexipafant group (p=0.023).
INFLAMMATORY MARKERS
Median (interquartile range) baseline values of
IL-8 were 31 (0–69) ng/l in the placebo group
and 37 (0–80) ng/l in the lexipafant group;
E-selectin values were 67 (51–100) µg/l and 70
(53–104) µg/l, respectively. IL-8 and E-selectin
levels increased compared with baseline values
at 12 hours in the placebo group but not in the
lexipafant group (figs 3, 4). Overall, changes
from baseline in IL-8 and E-selectin concentra-
tions were significantly diVerent, although
there were no diVerences in absolute values at
any time point. Values for IL-6, CRP, and
PMN elastase were not significantly diVerent
between the two groups (data not shown).
LENGTH OF HOSPITAL/ICU STAY
Median hospital stay for all patients was 10
(range 0–304) days in the placebo group and 9
(3–137) days in the lexipafant group. Hospital
stay in surviving patients was 9 (1–304) days in
the placebo group and 9 (3–137) days in the
lexipafant group. Twenty four of the lexipafant
treated patients and 25 of the placebo treated
patients were admitted to the ICU. Median
ICU stay was 11 (1–132) days in the placebo
group and 9.5 (1–71) days in the lexipafant
group. Of these, 12 in the placebo group and
eight in the lexipafant group died. In survivors,
median ICU stay was 12 (1–45) days in the
placebo group and 14 (5–71) days in the
lexipafant group. None of these observations
was significantly diVerent.
DEATHS
There were 21 (15%) attributable deaths in the
placebo group and 14 (10%) in the lexipafant
group (÷2=2.23, p=0.131). There were eight
attributable deaths in the placebo group versus
five in the lexipafant group during the first
week and 13 versus nine deaths after the first
week. Logistic regression analysis suggested
that the probability of death was significantly
reduced by early treatment with lexipafant
(p<0.05) (fig 5). All patients who died in the
Figure 2 Mean organ failure scores (OFS) in the placebo
and lexipafant groups (mean (SEM)). Values observed on
day 3 were significantly diVerent in the placebo and
treatment groups (p=0.039).















Figure 3 Median (interquartile range) changes in
interleukin 8 (IL-8) levels from baseline values given in the
text. Values observed 12 hours after the start of therapy
were significantly diVerent (p=0.006, Wilcoxon rank sum
test). Median area under the curve (AUC) for placebo was
0 (−499 to 9820) and for lexipafant –1.53 (−3890 to
1190) (p=0.003).


















Figure 4 Median (interquartile range) changes in
E-selectin levels from the baseline values given in the text.
Values observed 12 hours after the start of therapy were
significantly diVerent (p=0.005, Wilcoxon rank sum test).
Median area under the curve (AUC) for placebo was −0.0
(−24 to 130) and for lexipafant −1.3 (−95 to 77)
(p=0.03).






















Figure 5 Relationship between duration of symptoms
before treatment and risk of death, expressed as log odds
ratio of death in the lexipafant group compared with the
placebo group. Solid line, estimated ratio; broken lines, 95%
confidence intervals.
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first week had organ failure; all patients except
one who died subsequently had experienced
organ failure within the first week.
ADVERSE EVENTS
There were no significant diVerences in overall
or serious adverse events between the two
groups.
Discussion
This is the largest systematic prospective study
of severe acute pancreatitis ever undertaken
and has revealed new insights into the natural
history of the disease. Forty four per cent of
patients with a predicted severe attack
(APACHE II score >6 within 24 hours of
admission) had organ failure within 72 hours
of the onset of symptoms; new organ failure
developed in only 14% of patients after entry to
the study. Although the study design included
patients with an admission APACHE II score
>6, because previous reports indicated that the
proportion of patients developing a severe
complication (MODS and/or local pancreatic
complications) would be 45%,31 32 the high
incidence of organ failure at the time of entry to
the study meant that we could not test the pri-
mary end point of reduced frequency of
complications. The majority of organ failures
had occurred before initiation of treatment,
and the study lacked power to confirm an eVect
on the small numbers of new organ failure.
This new observation has important implica-
tions for the design of future studies in patients
with predicted severe acute pancreatitis
Eighty three per cent of patients who devel-
oped local pancreatic complications had early
organ failure; conversely, 36% of patients with
organ failure developed local pancreatic com-
plications. Nearly all deaths (34/35 or 97%)
occurred in patients who had early organ
failure.
These findings are contrary to the view that
death in the first week can be avoided by inten-
sive care support and that subsequent deaths
are due to local pancreatic complications which
can be managed eVectively by surgical inter-
vention.33 This perception is derived from
series with highly selected patient groups. In
contrast, the present population based study
showed that deaths occur both early and late,
principally from MODS. This is consistent
with the findings of a review of national figures
from Scotland, which included nearly 14 000
cases of acute pancreatitis. Of the patients who
died, 54% did so in the first seven days of
admission.34 The cause of these early deaths
was usually MODS.
A recent study has shown that pancreatic
necrosis is only predictive of death if MODS is
present as well.12 In the present study late deaths
also occurred, almost invariably in patients
who had early MODS, which lends support to
the two hit hypothesis of SIRS and MODS.35
The type of response of the immune system to
the first hit (onset of acute pancreatitis and
SIRS) determines the outcome during the
recovery phase from a second hit (such as sec-
ondary sepsis, gall stone obstruction of the
main pancreatic duct, bleeding, etc), resulting
either in a muZed re-enaction of SIRS or fatal
MODS.
The realisation that SIRS is an important
component of the pathophysiology of severe
acute pancreatitis,36 and that this might be sus-
ceptible to modification by antagonists of
known mediators of the inflammatory re-
sponse, provided reason to study lexipafant, a
PAF antagonist which is more potent in ligand
binding than PAF itself. The PAF molecule has
a major role in promoting and amplifying white
cell-endothelial interactions involving activa-
tion of various chemokines, cell adhesion mol-
ecules, and integrins, resulting in the ingress of
highly active white cells into the parenchyma
and consequent MODS.19 There was some
evidence that lexipafant treated patients
showed a more rapid reduction in plasma levels
of the inflammatory markers IL-6 and
E-selectin, although absolute values were not
diVerent. The only clinical correlate of this
observation was reduction in OFS on day 3 in
the lexipafant group, although there was no
overall diVerence in the numbers of patients
with organ failure. Interestingly, sepsis, a clini-
cally important expression of severe organ fail-
Table AI Study centres and participants
Centre Participating hospital Investigators Co-investigators
Belfast Royal Victoria Hospital, Belfast Professor BJ Rowlands Ms Mills
Birmingham Queen Elizabeth Hospital Professor JP Neoptolemos Dr P Wilson, Mr E Scott
Bristol Bristol Royal Infirmary Mr D Alderson Mr R Morgan, Ms S Norton, C Tookey
Dundee Ninewells Hospital Mr F Campbell, (Nov 94 to Mar 96)
Mr S Shimi (20 Mar 96 to end)
Mr N Noor, Ms M Hawkes, Ms J Roberts
Edinburgh Edinburgh Royal Infirmary Mr K Fearon Mr G Hill, Mrs J Stevenson
Glasgow Glasgow Royal Infirmary Prof C W Imrie, Mr C McKay Mr F Curran, Mr M Sinclair, Ms A McCarthy, Dr C Sharples
Leeds Leeds General Infirmary Professor M J McMahon Mr M Larvin
(from Feb 96)
Mr P Leeder, K Wilson, N Dewhirst
Liverpool Royal Liverpool Hospital Mr A Kingsnorth (10 Oct 94 to 11 Mar
96) Mr R Sutton (11 Mar 96 to end)
Mr P Scaife, Mrs L Tighe, Mr R Skaife
Leicester Leicester Royal Infirmary Mr DM Lloyd Mrs L Kilbourn
London Lewisham Hospital Mr M Larvin (Mar 95 to Feb 96) Mr R
Edmonson (Feb 96 to end)
Mr C Barben, Ms P Devane
West Middlesex University Hospital Mr RA L Young Mr D Heath, Mr C Barben, Ms P Devane
Newcastle The Medical School Professor FC Campbell Mr N Noor
Northampton Northampton General Hospital Mr A Berry Ms A Zak, Mrs A Fox
Oxford John RadcliVe Hospital Dr C Garrard, Mr J Britton Ms S Storer
Plymouth Derriford Hospital Mr C Brown (Jan 95 to Feb 96)
Professor A Kingsnorth (Feb 96 to end)
Dr L Campbell
SheYeld Royal Hallamshire Hospital Dr D Breen Ms S Smith
Southampton Southampton General Hospital Mr CD Johnson Mr S Toh, Ms D Slade
Swansea Morriston Hospital Dr D Thomas Ms L Jones, S Phillips, Mrs K Wareham
Lexipafant in the treatment and prevention of organ failure in acute pancreatitis 67
www.gutjnl.com
ure, was less frequent in the lexipafant treated
patients.
Two previous phase II randomised studies
showed more rapid reduction in OFSs without
the development of new organ failure in
lexipafant treated groups.14 25 In the present
study, with greater numbers of patients, there
was no significant eVect of lexipafant on the
development of new organ failure. In addition,
at the end of the treatment period there was no
diVerence in OFSs between the two groups, in
contrast with the findings in the smaller phase
II studies.14 25
Detection of pancreatic necrosis is depend-
ent on the rate of use of CT. As CT was
performed in only 41% of patients, data on
pancreatic necrosis need to be treated with cir-
cumspection. Nevertheless, the development of
pseudocysts and local complications in patients
with organ failure was also significantly re-
duced in the lexipafant group.
Post hoc logistic regression analysis showed
that treatment with lexipafant and earlier insti-
tution of therapy were highly related to a lower
mortality rate. However, the results of a much
larger phase III study do not support the
hypothesis that administration of lexipafant
within 48 hours of the onset of symptoms
reduces the mortality rate in severe acute pan-
creatitis (unpublished data).
In conclusion, the eYcacy of lexipafant was
rigorously tested (in a double blind manner)
within the general service provision of 78 hos-
pitals in the UK, principally district general
hospitals. There was a high frequency of organ
failure at study entry. Consequently, the study
failed to demonstrate its primary end point of a
reduction in the frequency of organ failure, and
it is now clear that the total frequency of organ
failure was not an appropriate end point for
assessment of new therapies in predicted severe
acute pancreatitis. There was no reduction in
new organ failure with lexipafant treatment.
Antagonism of PAF activity does not appear to
influence the course of organ failure in severe
acute pancreatitis.
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Appendix 1
Details of the study centres and participants
are given in table AI.
Appendix 2
Details of all participating hospitals are given in
table AII.
Appendix 3
Algorithm for interpolation of missing data
points to enable calculation of organ failure
scores for each day during the study treatment
Table AII Full list of participating hospitals
Centres Participating hospital
Belfast Royal Victoria Hospital
Ulster Hospital
Mater Informorum Hospital
Birmingham Queen Elizabeth Hospital
Good Hope District General Hospital
Selly Oak Hospital
Heartlands Hospital E Birmingham
City Hospital W Birmingham
Walsall Manor Hospital
Wolverhampton New Cross Hospital
Sandwell District General Hospital
Alexandra Hospital Redditch






Edinburgh Edinburgh Royal Infirmary







Western Infirmary/Gartnavel General Hospital





























West Middlesex University Hospital
Newcastle The Medical School
Northampton Northampton General Hospital
Oxford John RadcliVe Hospital
Plymouth Derriford Hospital
SheYeld Royal Hallamshire Hospital
Northern General Hospital
Rotherham District General Hospital
Chesterfield and North
Derbyshire Royal Hospital
Barnsley District General Hospital
Doncaster Royal Infirmary
Southampton Southampton General Hospital
Queen Alexandra Hospital Portsmouth
Royal Bournemouth and Christchurch Hospital
Poole General Hospital
Salisbury District Hospital
Royal Hampshire County Hospital Winchester
Royal South Hants Hospital
Royal Naval Hospital Haslar
Swansea Morriston Hospital
Singleton Hospital
Table AIII “Normal” values assigned in the algorithm for
interpolation of missing data points to enable calculation of
organ failure scores for each day during the study period,
where data were missing at day 0 or at hospital discharge







68 Johnson, Kingsnorth, Imrie, et al
www.gutjnl.com
period is described below. Where data were
missing at day 0 or at hospital discharge, “nor-
mal” values were assigned, as shown in table
AIII.
x Missing FiO2 values from day 0 to hospital
discharge were set at 21% (room air).
x If PaO2 was missing at all time points, it was
set at 11.5 kPa at any time point for which
FiO2 >21%.
x For any group of three consecutive time
points at which FiO2 was 21% or missing
and PaO2 was missing, the middle value of
PaO2 was set to 11.5 kPa (giving a PaO2/FiO2
ratio of 411.74—that is, 11.5 (0.21×0.133)).
x Where raw data were missing for any of days
1–7, missing values were estimated by linear
interpolation using available data from the
nearest days before and after the time point.
For example, the value of a parameter at day
k between days m and n was estimated by:
value at day k=value at day m+(k−m)
(n−m)×value at day n−value at day m). (In
the case of respiratory data, it is the
PaO2/FiO2 ratio, rather than PaO2, that is
interpolated).
x The last recorded OFSs of patients who died
were carried forward until the day of death.
If death occurred before day 7, scores of 0 for
any organ on the day of death were carried
forward up to day 7. Scores of >0 on the day
of death were replaced by 4 on the day of
death and carried forward up to day 7.
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